Market Research Reports

Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

145pages
Published Date: 2014-07-01
 

Description



Biological drugs have been touted as the drugs of the future because of their efficacy in treating life-threatening diseases such as cancer, auto-immune disorders as well as blood-related infections. This report conducts a detailed analysis of the biological drugs market to provide estimates and identify growth influencers. All analyses pertain to the forecast period ranging from 2014 to 2020, with 2013 being the base year.

The report is composed of different chapters, each of which dwells on specific aspects vital to the biological drugs market. These include: Market drivers, restraints, opportunities for growth and new trends on the horizon. Another important part of the report is the Company Profiles section which presents a summary of the operations of leading competing entities in the biological drugs market. 

Overview of the Biological Drugs Market

Biological drugs-also known as biologics-have marked a massive leap for the medical industry. These drugs are categorized as medical products that are derived from living beings. Biologics are available in a myriad of forms, including but not limited to: Vaccines, monoclonal antibody (mAb) and protein therapies.

The report notes that the biological drugs market will grow at a significant CAGR of 10.1% from 2014 to 2020, by which year it will be worth US$287,139.7 million. This healthy growth rate will be the result of the mounting cases of chronic diseases globally and the ability of biological drugs to treat them.  Analysts also forecast that the expanding geriatric population base will prove beneficial to the growth of the biologics market. The market will also reap the rewards of imminent breakthroughs in the biomedical sciences sector.

On the other hand, it will still be a while before patients and healthcare professionals accept biologics because these products are still expensive as compared to conventional drugs. Even as this market shifts into high gear, growth will be impeded as the patents of a few blockbuster drugs are on the verge of expiring. Biologic injectables are yet to enjoy widespread confidence because of their reported adverse effects on health.

For the purpose of this study, the global biological drugs market has been broadly segmented on the basis of: Vaccine, therapeutic protein, monoclonal antibody (mAb), and geography. Based on type of therapeutic protein, the global biological drugs market is sub-segmented as follows: Eylea, Enbrel, Neulasta, Lantus, Avonex, Rebif, NovoLog, Humalog, Epogen, Aranesp, Levemir, Betaseron, Victoza, and Neupogen. 

Similarly, mAb is sub-segmented into: Humira, Rituxan, Remicade, Avastin, Lucentis, and Herceptin. Likewise, the segment for vaccines is classified into: Gardasil, Prevnar 13, Fluzone, Cervarix and Varivax. 

The key geographical regions evaluated in the report are: North America, Asia, Europe, and Rest of the World (RoW), of which North America enjoys the lion’s share of the market. Asia, which offers cost and operational efficiencies to biological drug companies, has will see many investments in the coming years. 

Companies Mentioned in the Biological Drugs Market Report

The most prominent companies in the biological drugs market are: Biogen Idec, Abbott Laboratories, Pfizer Inc., Novartis AG, GlaxoSmithKline plc., Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., Merck & Co., Inc., and Baxter International Inc.

The global market of biological drugs is segmented as follows:

Biological Drugs Market, By Therapeutic Protein
  • Enbrel
  • Lantus
  • Neulasta
  • Avonex
  • NovoLog
  • Rebif
  • Humalog
  • Aranesp
  • Epogen
  • Levemir
  • Victoza
  • Betaseron
  • Neupogen
  • Eylea
Biological Drugs Market, By Monoclonal Antibody (mAb)
  • Humira
  • Remicade
  • Rituxan
  • Avastin
  • Herceptin
  • Lucentis
Biological Drugs Market, By Vaccine
  • Prenvar 13
  • Gardasil
  • Fluzone
  • Varivax
  • Cervarix
Biological Drugs Market, by Geography
  • North America
  • Europe
  • Asia
  • Rest of the World (RoW)
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Contents



Chapter 1 Preface
1.1 Report Description
1.2 Research methodology 
      1.2.1 Sources 
              1.2.1.1 Secondary Research 
              1.2.1.2 Primary Research
              1.2.1.3 Assumptions

Chapter 2 Executive Summary 

Chapter 3 Global Biological Drugs Market – Industry Analysis 
3.1 Introduction 
3.2 Market Drivers
      3.2.1 Increasing prevalence of chronic diseases enhance the market growth 
      3.2.2 Globally geriatric population increases the demand of biological drugs 
      3.2.3 Various government associations are promoting usage of biological drugs
3.3 Market Opportunities
      3.3.1 Advancement in biomedical science promises to boost the development of new biological products
3.4 Restraints 
      3.4.1 High cost of biological drugs impedes market growth
      3.4.2 Patent expiration of various blockbuster biological drugs
      3.4.3 Risk of adverse effects associated with biological injectable medicines

Chapter 4 Market Trends 
      4.1.1 Increasing use of anti-Vascular Endothelial Growth Factor (VEGF) therapy is gaining popularity in biopharmaceutical industry
      4.1.2 Genetically Modified Organisms (GMOs) are gaining importance in biological drugs market

Chapter 5 Porter’s Five Forces Analysis 
      5.1.1 Bargaining power of suppliers 
      5.1.2 Bargaining power of buyers 
      5.1.3 Threat of new entrants 
      5.1.4 Threat of substitutes 
      5.1.5 Degree of competition 

Chapter 6 Global Market Size and Forecast 

Chapter 7 Segment Analysis, by Therapeutic Protein 
7.1 Enbrel 
7.2 Lantus 
7.3 Neulasta 
7.4 Avonex 
7.5 NovoLog 
7.6 Rebif 
7.7 Humalog 
7.8 Aranesp 
7.9 Epogen
7.10 Levemir 
7.11 Victoza 
7.12 Betaseron
7.13 Neupogen
7.14 Eylea 

Chapter 8 Segment Analysis, by mAb 
8.1 Humira 
8.2 Remicade 
8.3 Rituxan 
8.4 Avastin 
8.5 Herceptin 
8.6 Lucentis 

Chapter 9 Segment Analysis, by Vaccine 
9.1 Prenvar 13 
9.2 Gardasil
9.3 Fluzone
9.4 Varivax 
9.5 Cervarix 

Chapter 10 Regional Analysis
10.1 Scenario in North America
10.2 Scenario in Europe 
10.3 Scenario in Asia 
10.4 Rest of the World (RoW) 

Chapter 11 Pipeline Biologic Drugs 
11.1 Biological drugs under development for auto-immune diseases 
11.2 Biological drugs under development for blood diseases 
11.3 Biological drugs under development for cancer and related conditions 
11.4 Biological drugs under development for diabetes and cardiovascular diseases 

Chapter 12 Competitive Landscape

Chapter 13 Company Profiles 
13.1 Pfizer Inc. 
      13.1.1 Company Overview 
      13.1.2 Product & Segments 
      13.1.3 Financial Performance 
      13.1.4 Strategic Developments 
13.2 Abbott Laboratories
      13.2.1 Company Overview
      13.2.2 Product & Segments 
      13.2.3 Financial Performance 
      13.2.4 Strategic Developments 
13.3 Novartis AG 
      13.3.1 Company Overview 
      13.3.2 Product & Segments 
      13.3.3 Financial Performance 
      13.3.4 Strategic Developments 
13.4 Eli Lilly and Company 
      13.4.1 Company Overview 
      13.4.2 Product & Segments 
      13.4.3 Financial Performance
      13.4.4 Strategic Developments
13.5 GlaxoSmithKline plc.
      13.5.1 Company Overview
      13.5.2 Product & Segments
      13.5.3 Financial Performance 
      13.5.4 Strategic Developments 
13.6 Bristol-Myers Squibb Company 
      13.6.1 Company Overview 
      13.6.2 Product & Segments 
      13.6.3 Financial Performance 
      13.6.4 Strategic Developments 
13.7 Merck & Co., Inc. 
      13.7.1 Company Overview 
      13.7.2 Product & Segments 
      13.7.3 Financial Performance 
      13.7.4 Strategic Developments 
13.8 Amgen Inc. 
      13.8.1 Company Overview 
      13.8.2 Product & Segments 
      13.8.3 Financial Performance 
      13.8.4 Strategic Developments 
13.9 Baxter International Inc. 
      13.9.1 Company Overview 
      13.9.2 Product & Segments 
      13.9.3 Financial Performance 
      13.9.4 Strategic Developments 
13.10 Biogen Idec 
      13.10.1 Company Overview 
      13.10.2 Product & Segments 
      13.10.3 Financial Performance 
      13.10.4 Strategic Developments 

List of Figures 

FIG. 1 Biological Drugs Market, by therapeutic proteins, mAbs and vaccine
FIG. 2 Geriatric population in major countries, % in older ages (2000-2050) 
FIG. 3 Biological Drugs Market: Porter’s five force analysis
FIG. 4 Global market for biological drugs, by geography 2013 (% share) 
FIG. 5 Global market for biological drugs, by segment 2013 (% share) 
FIG. 6 Global market for Enbrel, by geography 2013 (% share) 
FIG. 7 Global market for Lantus, by geography 2013 (% share) 
FIG. 8 Global market for Neulasta, by geography 2013 (% share) 
FIG. 9 Global market for Avonex, by geography 2013 (% share) 
FIG. 10 Global market for NovoLog, by geography 2013 (% share) 
FIG. 11 Global market for Rebif, by geography 2013 (% share) 
FIG. 12 Global market for Humalog, by geography 2013 (% share) 
FIG. 13 Global market for Aranesp, by geography 2013 (% share) 
FIG. 14 Global market for Epogen, by geography 2013 (% share) 
FIG. 15 Global market for Levemir, by geography 2013 (% share) 
FIG. 16 Global market for Victoza, by geography 2013 (% share) 
FIG. 17 Global market for Betaseron, by geography 2013 (% share)
FIG. 18 Global market for Neupogen, by geography 2013 (% share) 
FIG. 19 Global market for Eylea, by geography 2013 (% share) 
FIG. 20 Global market for Humira by geography 2013 (% share) 
FIG. 21 Global market for Remicade, by geography 2013 (% share) 
FIG. 22 Global market for Rituxan, by geography 2013 (% share) 
FIG. 23 Global market for Avastin, by geography 2013 (% share)
FIG. 24 Global market for Herceptin, by geography 2013 (% share)
FIG. 25 Global market for Lucentis, by geography 2013 (% share) 
FIG. 26 Global market for Prevnar 13, by geography 2013 (% share) 
FIG. 27 Global market for Gardasil, by geography 2013 (% share) 
FIG. 28 Global market for Fluzone, by geography 2013 (% share) 
FIG. 29 Global market for Varivax, by geography 2013 (% share) 
FIG. 30 Global market for Cervarix, by geography 2013 (% share)
FIG. 31 The North American market for biological drugs, by country 2013 (% share) 
FIG. 32 The North American market for biological drugs, by therapeutic protein 2013 (% share) 
FIG. 33 The North American market for biological drugs, by mAb 2013 (% share) 
FIG. 34 The North American market for biological drugs, by vaccine 2013 (% share)
FIG. 35 The European market for biological drugs, by country 2013 (% share)
FIG. 36 The European market for biological drugs, by therapeutic protein 2013 (% share) 
FIG. 37 The European market for biological drugs, by mAb 2013 (% share) 
FIG. 38 The European market for biological drugs, by vaccine 2013 (% share)
FIG. 39 The Asian market for biological drugs, by country 2013 (% share) 
FIG. 40 The Asian market for biological drugs, by therapeutic protein 2013 (% share) 
FIG. 41 The Asian market for biological drugs, by mAb 2013 (% share) 
FIG. 42 The Asian market for biological drugs, by vaccine 2013 (% share) 
FIG. 43 Competitive landscape of biological drugs market 
FIG. 44 Pfizer revenue and net income 2011-2013 (USD million) 
FIG. 45 Abbott net sales and net earnings 2011-2013 (USD million) 
FIG. 46 Novartis net sales and net income 2011-2013 (USD million) 
FIG. 47 Lilly revenue and net income 2011-2013 (USD million)
FIG. 48 GlaxoSmithKline turnover and profit 2011-2013 (USD million) 
FIG. 49 Bristol-Myers Squibb revenue and net earnings 2011-2013 (USD million) 
FIG. 50 Merck sales and net income 2011-2013 (USD million) 
FIG. 51 Amgen revenue and net income 2011-2013 (USD million) 
FIG. 52 Baxter net sales and net income 2011-2013 (USD million) 
FIG. 53 Biogen Idec revenue and net income 2011-2013 (USD million) 

List of Tables

TABLE 1 Market Snapshot: Global market for biological drugs (2014 & 2020) 
TABLE 2 Drivers for global biological drugs market: Impact analysis 
TABLE 3 Major biological drugs and their treatment for diseases 
TABLE 4 Restraints for global biological drugs market: Impact analysis 
TABLE 5 Major biological drugs and their adverse effects 21
TABLE 6 Global market for biological drugs, by geography 2009-2013 (USD million)
TABLE 7 Global market for biological drugs, by geography 2014-2020 (USD million)
TABLE 8 Global market for biological drugs , by segment 2009-2013 (USD million)
TABLE 9 Global market for biological drugs, by segment 2014-2020 (USD million) 
TABLE 10 Global market for Enbrel , by geography 2009-2013 (USD million) 
TABLE 11 Global market for Enbrel, by geography 2014-2020 (USD million) 
TABLE 12 Global market for Lantus , by geography 2009-2013 (USD million) 
TABLE 13 Global market for Lantus, by geography 2014-2020 (USD million) 
TABLE 14 Global market for Neulasta , by geography 2009-2013 (USD million) 
TABLE 15 Global market for Neulasta, by geography 2014-2020 (USD million) 
TABLE 16 Global market for Avonex, by geography 2009-2013 (USD million) 
TABLE 17 Global market for Avonex, by geography 2014-2020 (USD million) 
TABLE 18 Global market for NovoLog , by geography 2009-2013 (USD million) 
TABLE 19 Global market for NovoLog, by geography 2014-2020 (USD million) 
TABLE 20 Global market for Rebif, by geography 2009-2013 (USD million) 
TABLE 21 Global market for Rebif, by geography 2014-2020 (USD million) 
TABLE 22 Global market for Humalog, by geography 2009-2013 (USD million)
TABLE 23 Global market for Humalog, by geography 2014-2020 (USD million) 
TABLE 24 Global market for Aranesp, by geography 2009-2013 (USD million) 
TABLE 25 Global market for Aranesp, by geography 2014-2020 (USD million) 
TABLE 26 Global market for Epogen, by geography 2009-2013 (USD million) 
TABLE 27 Global market for Epogen, by geography 2014-2020 (USD million) 
TABLE 28 Global market for Levemir, by geography 2009-2013 (USD million) 
TABLE 29 Global market for Levemir, by geography 2014-2020 (USD million) 
TABLE 30 Global market for Victoza, by geography 2009-2013 (USD million)
TABLE 31 Global market for Victoza, by geography 2014-2020 (USD million) 
TABLE 32 Global market for Betaseron, by geography 2009-2013 (USD million) 
TABLE 33 Global market for Betaseron, by geography 2014-2020 (USD million) 
TABLE 34 Global market for Neupogen, by geography 2009-2013 (USD million)
TABLE 35 Global market for Neupogen, by geography 2014-2020 (USD million) 
TABLE 36 Global market for Eylea, by geography 2009-2013 (USD million) 
TABLE 37 Global market for Eylea, by geography 2014-2020 (USD million) 
TABLE 38 Global market for Humira, by geography 2009-2013 (USD million) 
TABLE 39 Global market for Humira, by geography 2014-2020 (USD million) 
TABLE 40 Global market for Remicade, by geography 2009-2013 (USD million) 
TABLE 41 Global market for Remicade, by geography 2014-2020 (USD million) 
TABLE 42 Global market for Rituxan, by geography 2009-2013 (USD million) 
TABLE 43 Global market for Rituxan, by geography 2014-2020 (USD million) 
TABLE 44 Global market for Avastin, by geography 2009-2013 (USD million) 
TABLE 45 Global market for Avastin, by geography 2014-2020 (USD million) 
TABLE 46 Global market for Herceptin, by geography 2009-2013 (USD million)
TABLE 47 Global market for Herceptin, by geography 2014-2020 (USD million)
TABLE 48 Global market for Lucentis, by geography 2009-2013 (USD million)
TABLE 49 Global market for Lucentis, by geography 2014-2020 (USD million) 
TABLE 50 Global market for Prevnar 13, by geography 2009-2013 (USD million)
TABLE 51 Global market for Prevnar 13, by geography 2014-2020 (USD million) 
TABLE 52 Global market for Gardasil, by geography 2009-2013 (USD million) 
TABLE 53 Global market for Gardasil, by geography 2014-2020 (USD million)
TABLE 54 Global market for Fluzone, by geography 2009-2013 (USD million) 
TABLE 55 Global market for Fluzone, by geography 2014-2020 (USD million) 
TABLE 56 Global market for Varivax, by geography 2009-2013 (USD million) 
TABLE 57 Global market for Varivax, by geography 2014-2020 (USD million) 
TABLE 58 Global market for Cervarix, by geography 2009-2013 (USD million) 
TABLE 59 Global market for Cervarix, by geography 2014-2020 (USD million) 
TABLE 60 The North American market for biological drugs, by country 2009-2013 (USD million) 
TABLE 61 The North American market for biological drugs, by country 2014-2020 (USD million)
TABLE 62 The North American market for biological drugs, by therapeutic protein 2009-2013 (USD million)
TABLE 63 The North American market for biological drugs, by therapeutic protein 2014-2020 (USD million) 
TABLE 64 The North American market for biological drugs, by mAb 2009-2013 (USD million) 
TABLE 65 The North American market for biological drugs, by mAb 2014-2020 (USD million) 
TABLE 66 The North American market for biological drugs, by vaccine 2009-2013 (USD million) 
TABLE 67 The North American market for biological drugs, by vaccine 2014-2020 (USD million) 
TABLE 68 The European market for biological drugs, by country 2009-2013 (USD million) 
TABLE 69 The European market for biological drugs, by country 2014-2020 (USD million) 
TABLE 70 The European market for biological drugs, by therapeutic protein 2009-2013 (USD million)
TABLE 71 The European market for biological drugs, by therapeutic protein 2014-2020 (USD million) 
TABLE 72 The European market for biological drugs, by mAb 2009-2013 (USD million) 
TABLE 73 The European market for biological drugs, by mAb 2014-2020 (USD million) 
TABLE 74 The European market for biological drugs, by vaccine 2009-2013 (USD million) 
TABLE 75 The European market for biological drugs, by vaccine 2014-2020 (USD million) 
TABLE 76 The Asian market for biological drugs, by country 2009-2013 (USD million) 
TABLE 77 The Asian market for biological drugs, by country 2014-2020 (USD million)
TABLE 78 The Asian market for biological drugs, by therapeutic protein 2009-2013 (USD million)
TABLE 79 The Asian market for biological drugs, by therapeutic protein 2014-2020 (USD million)
TABLE 80 The Asian market for biological drugs, by mAb 2009-2013 (USD million) 101
TABLE 81 The Asian market for biological drugs, by mAb 2014-2020 (USD million) 102
TABLE 82 The Asian market for biological drugs, by vaccine 2009-2013 (USD million) 
TABLE 83 The Asian market for biological drugs, by vaccine 2014-2020 (USD million) 
TABLE 84 Some pipeline biological drugs for auto-immune diseases 
TABLE 85 Some pipeline biological drugs for blood diseases
TABLE 86 Some pipeline biological drugs for cancer and related conditions 
TABLE 87 Some pipeline biological drugs for diabetes and cardiovascular diseases
TABLE 88 Pfizer major product segments 
TABLE 89 Abbott major product categories 
TABLE 90 Novartis product segments 
TABLE 91 Lilly product segments 
TABLE 92 GlaxoSmithKline product segments
TABLE 93 Bristol-Myers Squibb key product and brands 
TABLE 94 Merck key product categories 
TABLE 95 Amgen product category 
TABLE 96 Baxter major product categories 
TABLE 97 Biogen Idec major therapies and their uses 

Enquiry Before Buying


Free Market Analysis


Globally, the biological drugs market is witnessing a significant growth due to increasing prevalence of various chronic diseases, as the demand for biological drugs is increasing with the rise in the global geriatric population. The biological drugs are used in the treatment and prevention of various diseases, such as blood related diseases, cancer, auto-immune diseases and other medical disorders. Additionally, various government associations are promoting the usage of biological drugs. Moreover, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020.  

North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein. In monoclonal antibody (mAb), Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine.

The global biological drugs market was valued at 1, 01,656.5 million in 2009 and it expanded to USD 1, 46,548.2 million in 2013 growing at a CAGR of 9.6% from 2009 to 2013.

biological-drugs-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research